Reynoso Jamie L. sold $22K of CLOV

Reynoso Jamie L. (CEO, Medicare Advantage) sold 4,839 shares of CLOVER HEALTH INVESTMENTS, CORP. /DE (CLOV) at $4.53 on 2026-07-17 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Reynoso Jamie L.
Published Jul 17, 2026, 9:26 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 17, 2026, 9:35 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$CLOV
Neutral
medium confidence
Mentioned
$CLOV
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CLOVNeutralLow
01

Why it matters

The CEO’s open-market sale at a stated price is disclosed as part of a pre-arranged 10b5-1 plan, which generally lowers the informational content versus unscheduled selling.

02

Market read

Traders may note the insider sale for sentiment, but the 10b5-1 structure suggests limited fundamental implication.

03

What to watch

The filing does not indicate whether other insiders or the company simultaneously made offsetting purchases, nor does it provide context on total insider activity beyond this single transaction.

Relevance 2/10Novelty 4/10Timing: Filed 2026-07-17 after-hours/late session, relevant for next session positioning.

Background

The article is an SEC Form 4 insider transaction disclosure for Clover Health Investments Corp. (CLOV).

Company-level read

Ticker impact

$CLOVNeutralMedium confidence
Context

Clover Health CEO Jamie L. Reynoso sold 4,839 shares in an open-market transaction at $4.5300 on 2026-07-17 under a 10b5-1 plan.

Expected impact

Low likelihood of a sustained price move; any impact is likely short-lived and sentiment-driven.

Evidence & confidence

The filing is a Form 4 insider sale, but it is explicitly under a pre-arranged Rule 10b5-1 plan, which typically reduces interpretive weight versus discretionary selling.

Market effects

Minimal read-through to the broader healthcare/Medicare Advantage sector; this is company-specific insider trading disclosure.

None.

None.

Counterpoint

Because the sale is under a 10b5-1 plan, it may reflect scheduled liquidity needs rather than bearish expectations, so traders may discount the signal.

Key entities

  • CLOV

    Clover Health Investments Corp. (DE), the company whose CEO filed the Form 4 insider sale.

  • Reynoso Jamie L.

    CEO, Medicare Advantage, who sold 4,839 shares on 2026-07-17.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$UNHMed

Medicare, Medicaid Overhaul Targets Fraudulent Billing and Unauthorized Marketplace Enrollments

CMS proposed reforms to combat fraud in Medicare, Medicaid, CHIP, and the Health Insurance Marketplace, aiming to save $90B over 10 years. The rule strengthens oversight, requires self-reporting of overpayments, and increases transparency. Managed care stocks fell, including UNH, HUM, CVS, CLOV, CNC, MOH, ELV, and OSCR. Medicare anti-fraud efforts saved $41.9B in 2025, with a $22.30 return per dollar spent.

$HUMHighAI 9/10

Humana (HUM) Stock Hits New 52-Week High

Humana (HUM) reached a new 52-week high after reporting Q3 2026 earnings with a smaller loss and raised full-year EPS guidance. Competitors like CVS Health and Elevance Health also saw gains. Clover Health (CLOV) reported Q3 2026 earnings with a slight profit and raised full-year targets.

$CLOVHighAI 8/10

Clover Health (CLOV) Q3 2026 Earnings Call Transcript

Clover Health (CLOV) reported Q3 2026 earnings, highlighting 49% YoY membership growth to 157,000 members, 57% revenue increase to $2.3B, and doubled adjusted EBITDA to $97M. The company achieved high Star Ratings for its plans and improved HEDIS quality performance. Clover Assistant's engagement accelerated, driving better care and economics. The board appointed Clay Thornton as permanent CFO. Management expects continued growth and profitability in 2027 and 2028.